ArticleCell death & disease2026
A new candidate tumor suppressor tRF-Ser inhibits gastric cancer progression by regulating the CNBP/HSPA8 axis.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is a highly aggressive malignancy with a poor prognosis. Transfer RNA-derived small RNAs (tsRNAs) are implicated in tumorigenesis, but their precise mechanistic roles in GC progression remain incompletely understood. We performed high-throughput sequencing in four paired GC/normal tissues to profile tsRNAs. The functional and mechanistic role of a candidate tsRNA was systematically investigated, alongside a suite of techniques including fluorescence in situ hybridization, RNA immunoprecipitation, RNA pull-down, chromatin immunoprecipitation, and luciferase reporter assays. We identified a novel tsRNA, tRF-Ser, that was significantly downregulated in GC tissues and cell lines, and its expression was correlated with favorable survival. Functionally, tRF-Ser acted as a tumor suppressor by inhibiting epithelial-mesenchymal transition (EMT), inducing ferroptosis, and enhancing sensitivity to 5-fluorouracil chemotherapy. Mechanistically, tRF-Ser directly bound to the cellular nucleic acid-binding protein CNBP (a transcription factor), promoting its accumulation in the cytoplasm and preventing its binding to the HSPA8 promoter to downregulate HSPA8. Then, the tRF-Ser/CNBP/HSPA8 axis suppressed EMT by inhibiting β-catenin nuclear translocation and promoted ferroptosis by facilitating STUB1-mediated ubiquitination degradation of GPX4. Our study unveils that the tRF-Ser/CNBP/HSPA8 axis may constrain GC progression by regulating energy metabolism, which highlights the therapeutic potential of targeting this axis for GC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.